CoChat
Sign Up
Cited by 1,355Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and DiagnosticsAcute Myocardial Infarction Research

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery

Open access
Levine, Glenn N., Bates, Eric R., Bittl, John A., Brindis, Ralph G., Fihn, Stephan D., Fleisher, Lee A., Granger, Christopher B., Lange, Richard A. +9 more·2016·Circulation
DOI 10.1161/cir.0000000000000404
Open this paper in CoChat — free accountOpen PDF

Abstract

An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/cir.0000000000000404

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Combination dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is indicated after acute coronary syndromes and coronary revascularization with stenting.

    “Combination dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is indicated after acute coronary syndromes and coronary revascularization with stenting (197).”

    From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [197]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 89

  1. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US) . Clinical Practice Guidelines We Can Trust . Washington, DC: National Academies Press; 2011 .
  2. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US) . Finding What Works in Health Care: Standards for Systematic Reviews . Wash- ington, DC: National Academies Press; 2011 .
  3. Anderson JL, Heidenreich PA, Barnett PG, et al . ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Perfor- mance Measures and Task Force on Practice Guidelines . Circula- tion . 2014;129:2329-45 .
  4. Arnett DK, Goodman RA, Halperin JL, et al . AHA/ACC/HHS strate- gies to enhance application of clinical practice guidelines in pa- tients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U .S . Department of Health and Human Services . Circulation . 2014;130:1662-67 .
  5. Jacobs AK, Kushner FG, Ettinger SM, et al . ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines . Circulation . 2013;127:268-310 .
  6. Jacobs AK, Anderson JL, Halperin JL . The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines . Circulation . 2014;130:1208-17 .
  7. Halperin JL, Levine GN, Al-Khatib SM, et al . Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classi- fication System: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guide- lines . Circulation . 2016;133:1426-1428 .
  8. Levine GN, Bates ER, Blankenship JC, et al . 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions . Circulation . 2011;124:e574-651 .
  9. Hillis LD, Smith PK, Anderson JL, et al . 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines . Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascu- lar Anesthesiologists, and Society of Thoracic Surgeons . Circulation . 2011;124:e652-735 .
  10. Fihn SD, Gardin JM, Abrams J, et al . 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart As- sociation Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardio- vascular Angiography and Interventions, and Society of Thoracic Surgeons . Circulation . 2012;126:3097-137 .
  11. O'Gara PT, Kushner FG, Ascheim DD, et al . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarc- tion: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines . Circulation . 2013;127:e362-425 .
  12. Amsterdam EA, Wenger NK, Brindis RG, et al . 2014 AHA/ACC guideline for the management of patients with non─ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines . Circulation . 2014;130:e344-426 .
  13. Fleisher LA, Fleischmann KE, Auerbach AD, et al . 2014 ACC/ AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines . Circulation . 2014;130:e278-333 .
  14. Mauri L, Kereiakes DJ, Yeh RW, et al . Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents . N Engl J Med . 2014;371:2155-66 .
  15. Colombo A, Chieffo A, Frasheri A, et al . Second-generation drug- eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial . J Am Coll Cardiol . 2014;64:2086-97 .
  16. Gwon H-C, Hahn J-Y, Park KW, et al . Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study . Circulation . 2012;125:505-13 .
  17. Kim B-K, Hong M-K, Shin D-H, et al . A new strategy for discon- tinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following En- deavor zotarolimus-eluting stent implantation) . J Am Coll Cardiol . 2012;60:1340-8 .
  18. Feres F, Costa RA, Abizaid A, et al . Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial . JAMA . 2013;310:2510-22 .
  19. Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al . ISAR-SAFE: a ran- domized, double-blind, placebo-controlled trial of 6 vs . 12 months of clopidogrel therapy after drug-eluting stenting . Eur Heart J . 2015;36:1252-63 .
  20. Park S-J, Park D-W, Kim Y-H, et al . Duration of dual antiplatelet therapy after implantation of drug-eluting stents . N Engl J Med . 2010;362:1374-82 .
  21. Valgimigli M, Campo G, Monti M, et al . Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a ran- domized multicenter trial . Circulation . 2012;125:2015-26 .
  22. Collet J-P, Silvain J, Barthélémy O, et al . Dual-antiplatelet treat- ment beyond 1 year after drug-eluting stent implantation (ARCTIC- Interruption): a randomised trial . Lancet . 2014;384:1577-85 .
  23. Gilard M, Barragan P, Noryani AAL, et al . 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in pa- tients nonresistant to aspirin: the randomized, multicenter ITALIC trial . J Am Coll Cardiol . 2015;65:777-86 .
  24. Lee CW, Ahn J-M, Park D-W, et al . Optimal duration of dual anti- platelet therapy after drug-eluting stent implantation: a random- ized, controlled trial . Circulation . 2014;129:304-12 .
  25. Helft G, Steg PG, Le Feuvre C, et al . Stopping or continuing clopi- dogrel 12 months after drug-eluting stent placement: the OPTIDU- AL randomized trial . Eur Heart J . 2016;37:365-74 .
  26. Roffi M, Patrono C, Collet J-P, et al . 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Manage- ment of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiol- ogy (ESC) . Eur Heart J . 2016;37:267-315 .
  27. Bittl JA, Baber U, Bradley SM, et al . Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines . Circulation . 2016;134:e156-e178 .
  28. Steg PG, James SK, Atar D, et al . ESC guidelines for the manage- ment of acute myocardial infarction in patients presenting with ST-segment elevation . Eur Heart J . 2012;33:2569-619 .
  29. Wijns W, Kolh P, Danchin N, et al . Guidelines on myocardial revas- cularization . Eur Heart J . 2010;31:2501-55 .
  30. Hamm CW, Bassand J-P, Agewall S, et al . ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Eleva- tion of the European Society of Cardiology (ESC) . Eur Heart J . 2011;32:2999-3054 .
  31. Palmerini T, Sangiorgi D, Valgimigli M, et al . Short-versus long- term dual antiplatelet therapy after drug-eluting stent implanta- tion: an individual patient data pairwise and network meta-analy- sis . J Am Coll Cardiol . 2015;65:1092-102 . Circulation. 2016;134:e123-e155. DOI: 10.1161/CIR.0000000000000404 September 6, 2016 e145 · DOI
  32. Palmerini T, Benedetto U, Bacchi-Reggiani L, et al . Mortality in pa- tients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials . Lancet . 2015;385:2371-82 .
  33. Giustino G, Baber U, Sartori S, et al . Duration of dual antiplate- let therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials . J Am Coll Cardiol . 2015;65:1298-310 .
  34. Navarese EP, Andreotti F, Schulze V, et al . Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials . BMJ . 2015;350:h1618 .
  35. Navarese EP, Tandjung K, Claessen B, et al . Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis . BMJ . 2013;347:f6530 .
  36. Hermiller JB, Krucoff MW, Kereiakes DJ, et al . Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents . JACC Cardiovasc Interv . 2016;9:138-47 .
  37. Bhatt DL, Fox KAA, Hacke W, et al . Clopidogrel and aspirin ver- sus aspirin alone for the prevention of atherothrombotic events . N Engl J Med . 2006;354:1706-17 .
  38. Bhatt DL, Flather MD, Hacke W, et al . Patients with prior myocar- dial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial . J Am Coll Cardiol . 2007;49:1982-8 .
  39. Yeh RW, Kereiakes DJ, Steg PG, et al . Benefits and risks of ex- tended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction . J Am Coll Cardiol . 2015;65:2211-21 .
  40. Udell JA, Bonaca MP, Collet J-P, et al . Long-term dual antiplate- let therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials . Eur Heart J . 2016;37:390-9 .
  41. Mauri L, Elmariah S, Yeh RW, et al . Causes of late mortality with dual antiplatelet therapy after coronary stents . Eur Heart J . 2016;37:378-85 .
  42. Spencer FA, Prasad M, Vandvik PO, et al . Longer versus shorter- duration dual-antiplatelet therapy after drug-eluting stent place- ment: a systematic review and meta-analysis . Ann Intern Med . 2015;163:118-26 .
  43. Montalescot G, Brieger D, Dalby AJ, et al . Duration of dual anti- platelet therapy after coronary stenting: a review of the evidence . J Am Coll Cardiol . 2015;66:832-47 .
  44. Elmariah S, Mauri L, Doros G, et al . Extended duration dual an- tiplatelet therapy and mortality: a systematic review and meta- analysis . Lancet . 2015;385:792-8 .
  45. US Food and Drug Administration . FDA Drug Safety Communi- cation: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death . Avail- able at: http://www .fda .gov/Drugs/DrugSafety/ucm471286 .htm . Published November 6, 2015; updated December 9, 2015 ac- cessed February 17, 2016 .
  46. Steinhubl SR, Berger PB, Mann JT 3rd, et al . Early and sustained dual oral antiplatelet therapy following percutaneous coronary in- tervention: a randomized controlled trial . JAMA . 2002;288:2411- 20 .
  47. Mehta SR, Yusuf S, Peters RJ, et al . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study . Lancet . 2001;358:527-33 .
  48. Montalescot G, Wiviott SD, Braunwald E, et al . Prasugrel com- pared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRI- TON-TIMI 38): double-blind, randomised controlled trial . Lancet . 2009;373:723-31 .
  49. Antithrombotic Trialists' Collaboration . Collaborative meta-analy- sis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients . BMJ . 2002;324:71-86 .
  50. Patrono C, Baigent C, Hirsh J, et al . Antiplatelet drugs: Ameri- can College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) . Chest . 2008;133:199S-233S .
  51. Peters RJG, Mehta SR, Fox KAA, et al . Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopi- dogrel in Unstable angina to prevent Recurrent Events (CURE) study . Circulation . 2003;108:1682-7 .
  52. Steinhubl SR, Bhatt DL, Brennan DM, et al . Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding . Ann Intern Med . 2009;150:379-86 .
  53. Mehta SR, Tanguay J-F, Eikelboom JW, et al . Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial . Lancet . 2010;376:1233-43 .
  54. Yeh RW, Secemsky E, Kereiakes DJ, et al . Development and vali- dation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond one year after percutaneous coronary interven- tion: an analysis from the randomized Dual Antiplatelet Therapy Study . JAMA . In Press .
  55. Califf RM, Armstrong PW, Carver JR, et al . 27th Bethesda Confer- ence: matching the intensity of risk factor management with the hazard for coronary disease events . Task Force 5 . Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management . J Am Coll Cardiol . 1996;27:1007-19 .
  56. Sachdev M, Sun JL, Tsiatis AA, et al . The prognostic importance of co- morbidity for mortality in patients with stable coronary artery disease . J Am Coll Cardiol . 2004;43:576-82 .
  57. Binder RK, Lüscher TF, O'Connor SA . Duration of dual anti- platelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding? Eur Heart J . 2015;36:1207-11 .
  58. Subherwal S, Bach RG, Chen AY, et al . Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementa- tion of the ACC/AHA Guidelines) Bleeding Score . Circulation . 2009;119:1873-82 .
  59. Moscucci M, Fox KA, Cannon CP, et al . Predictors of major bleed- ing in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) . Eur Heart J . 2003;24:1815-23 .
  60. Mehran R, Pocock SJ, Nikolsky E, et al . A risk score to predict bleeding in patients with acute coronary syndromes . J Am Coll Cardiol . 2010;55:2556-66 .
  61. Baber U, Mehran R, Sharma SK, et al . Impact of the everolimus- eluting stent on stent thrombosis: a meta-analysis of 13 random- ized trials . J Am Coll Cardiol . 2011;58:1569-77 .
  62. Cayla G, Hulot J-S, O'Connor SA, et al . Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis . JAMA . 2011;306:1765-74 .
  63. Campo G, Tebaldi M, Vranckx P, et al . Short-versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) . J Am Coll Cardiol . 2014;63:506-12 .
  64. James SK, Roe MT, Cannon CP, et al . Ticagrelor versus clopido- grel in patients with acute coronary syndromes intended for non- invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial . BMJ . 2011;342:d3527 .
  65. Steg PG, James S, Harrington RA, et al . Ticagrelor versus clopi- dogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary in- tervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis . Circulation . 2010;122:2131-41 .
  66. Abraham NS, Hlatky MA, Antman EM, et al . ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ ACG/AHA 2008 expert consensus document on reducing the gas- trointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents . Circulation . 2010;122:2619-33 .
  67. Serebruany VL, Steinhubl SR, Berger PB, et al . Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials . Am J Cardiol . 2005;95:1218-22 .
  68. Jolly SS, Pogue J, Haladyn K, et al . Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study . Eur Heart J . 2009;30:900-7 .
  69. Lorenz RL, Schacky CV, Weber M, et al . Improved aortocoro- nary bypass patency by low-dose aspirin (100 mg daily): effects on platelet aggregation and thromboxane formation . Lancet . 1984;1:1261-4 .
  70. Xian Y, Wang TY, McCoy LA, et al . Association of discharge aspirin dose with outcomes after acute myocardial infarction: insights from the Treatment with ADP Receptor Inhibitors: Lon- gitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study . Circulation . 2015;132:174-81 .
  71. Montalescot G, Drobinski G, Maclouf J, et al . Evaluation of thromboxane production and complement activation during myo- cardial ischemia in patients with angina pectoris . Circulation . 1991;84:2054-62 .
  72. Patrono C, Ciabattoni G, Patrignani P, et al . Clinical phar- macology of platelet cyclooxygenase inhibition . Circulation . 1985;72:1177-84 .
  73. Steinhubl SR, Berger PB . Aspirin following PCI: too much of a good thing? Eur Heart J . 2009;30:882-4 .
  74. Dans AL, Connolly SJ, Wallentin L, et al . Concomitant use of an- tiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial . Circulation . 2013;127:634-40 .
  75. Faxon DP, Eikelboom JW, Berger PB, et al . Consensus document: antithrombotic therapy in patients with atrial fibrillation undergo- ing coronary stenting: a North-American perspective . Thromb Haemost . 2011;106:572-84 .
  76. Sørensen R, Hansen ML, Abildstrom SZ, et al . Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data . Lancet . 2009;374:1967-74 .
  77. Lip GYH, Windecker S, Huber K, et al . Management of antithrom- botic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) . Eur Heart J . 2014;35:3155-79 .
  78. Fiedler KA, Maeng M, Mehilli J, et al . Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial . J Am Coll Cardiol . 2015;65:1619-29 .
  79. Dewilde WJM, Janssen PWA, Verheugt FWA, et al . Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review . J Am Coll Cardiol . 2014;64:1270-80 .
  80. Moser M, Olivier CB, Bode C . Triple antithrombotic therapy in cardiac patients: more questions than answers . Eur Heart J . 2014;35:216-23 .
  81. Capodanno D, Angiolillo DJ . Management of antiplatelet and an- ticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interven- tions . Circ Cardiovasc Interv . 2014;7:113-24 .
  82. Leon MB, Baim DS, Popma JJ, et al . A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stent- ing . Stent Anticoagulation Restenosis Study Investigators . N Engl J Med . 1998;339:1665-71 .
  83. Schömig A, Neumann FJ, Kastrati A, et al . A randomized compar- ison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents . N Engl J Med . 1996;334:1084-9 .
  84. Brar SS, Kim J, Brar SK, et al . Long-term outcomes by clopido- grel duration and stent type in a diabetic population with de novo coronary artery lesions . J Am Coll Cardiol . 2008;51:2220-7 .
  85. Eisenstein EL, Anstrom KJ, Kong DF, et al . Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation . JAMA . 2007;297:159-68 .
  86. Sabatine MS, Cannon CP, Gibson CM, et al . Effect of clopidogrel pretreatment before percutaneous coronary intervention in pa- tients with ST-elevation myocardial infarction treated with fibrino- lytics: the PCI-CLARITY study . JAMA . 2005;294:1224-32 .
  87. Cutlip DE, Baim DS, Ho KK, et al . Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials . Circulation . 2001;103:1967-71 . 100 . Wilson SH, Rihal CS, Bell MR, et al . Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin . Am J Cardiol . 1999;83:1006-11 . 101 . Kaluza GL, Joseph J, Lee JR, et al . Catastrophic outcomes of non- cardiac surgery soon after coronary stenting . J Am Coll Cardiol . 2000;35:1288-94 . Circulation. 2016;134:e123-e155. DOI: 10.1161/CIR.0000000000000404 September 6, 2016 e147 102 . · DOI
  88. Wilson SH, Fasseas P, Orford JL, et al . Clinical outcome of pa- tients undergoing non-cardiac surgery in the two months follow- ing coronary stenting . J Am Coll Cardiol . 2003;42:234-40 . 103 . Nuttall GA, Brown MJ, Stombaugh JW, et al . Time and cardiac risk of surgery after bare-metal stent percutaneous coronary in- tervention . Anesthesiology . 2008;109:588-95 . 104 . Grines CL, Bonow RO, Casey DE, et al . Prevention of prema- ture discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with represen- tation from the American College of Physicians . Circulation . 2007;115:813-8 . 105 . Pfisterer M, Brunner-La Rocca HP, Buser PT, et al . Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents . J Am Coll Cardiol . 2006;48:2584-91 . 106 . Navarese EP, Kowalewski M, Kandzari D, et al . First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients . Open Heart . 2014;1:e000064 . 107 .
  89. Palmerini T, Kirtane AJ, Serruys PW, et al . Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative random- ized controlled trials . Circ Cardiovasc Interv . 2012;5:357-64 . 108 . Räber L, Magro M, Stefanini GG, et al . Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent com- pared with early-generation drug-eluting stents: a prospective cohort study . Circulation . 2012;125:1110-21 . 109 . Sarno G, Lagerqvist B, Nilsson J, et al . Stent thrombosis in new-generation drug-eluting stents in patients with STEMI un- dergoing primary PCI: a report from SCAAR . J Am Coll Cardiol . 2014;64:16-24 . 110 . Kočka V, Malý M, Toušek P, et al . Bioresorbable vascular scaf- folds in acute ST-segment elevation myocardial infarction: a prospective multicentre study "Prague 19" . Eur Heart J . 2014;35:787-94 . 111 . Kereiakes DJ, Meredith IT, Windecker S, et al . Efficacy and safety of a novel bioabsorbable polymer-coated, everolim- us-eluting coronary stent: the EVOLVE II Randomized Trial . Circ Cardiovasc Interv . 2015;8:e002372 . DOI: 10 .1161/ CIRCINTERVENTIONS .114 .002372 . 112 . Puricel S, Arroyo D, Corpataux N, et al . Comparison of evero- limus-and biolimus-eluting coronary stents with everolimus- eluting bioresorbable vascular scaffolds . J Am Coll Cardiol . 2015;65:791-801 . 113 . Gao R, Yang Y, Han Y, et al . Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial . J Am Coll Cardiol . 2015;66:2298-309 . 114 . Windecker S, Serruys PW, Wandel S, et al . Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a ran- domised non-inferiority trial . Lancet . 2008;372:1163-73 . 115 . · DOI

Cited by

Sorted by citations

Authors
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., Mehran, R., Mukherjee, D., Newby, L. K., O’Gara, P. T., Sabatine, M. S., Smith, P. K., & Smith, S. C.
Affiliations
Focused Update writing group members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1 for detailed information. ACC/AHA Task Force on Clinical Practice Guidelines Liaison. ACC/AHA Representative. Evidence Review Committee Chair. American Society of Anesthesiologists/Society of Cardiovascular Anesthesiologists Representative. American Association for Thoracic Surgery/Society of Thoracic Surgeons Representative....
ORCID
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-09-06
Volume
134
Issue
10
Pages
e123-55
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
DOI
10.1161/cir.0000000000000404
OpenAlex
W4211143229
Cited by
1,355
References
10
Citations by year
2026: 71 · 2025: 111 · 2024: 142 · 2023: 163 · 2022: 172 · 2021: 161 · 2020: 157 · 2019: 123 · 2018: 123 · 2017: 107 · 2016: 23 · 2014: 1
FWCI
103.49
Type
journal article
Language
en
Update notices
correction (2016-09-06)
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Heart Association
  • Society of Thoracic Surgeons
  • Society of Cardiovascular Anesthesiologists
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
dual antiplatelet therapy, antiplatelet therapy duration, coronary artery disease, percutaneous coronary intervention, coronary artery bypass grafting, stable coronary artery disease, ST-elevation myocardial infarction, non-ST-elevation acute coronary syndrome, non-cardiac surgery
MeSH terms
American Heart Association, Coronary Artery Bypass, Cardiology, Coronary Artery Disease, Humans, Myocardial Infarction, Platelet Aggregation Inhibitors, Societies, Medical, United States, Myocardial Ischemia, Practice Guidelines as Topic, Disease Management, Perioperative Care, Advisory Committees, Acute Coronary Syndrome, Research Report, Percutaneous Coronary Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review